SS Innovations International (SSII) AI Stock Analysis

• Market Cap: $708.65M
• Dividend Yield: N/A
• Average Volume (3M): 74.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 9.95
• Revenue Growth: 159.43%
• EPS Growth: 67.42%
• Country: US
• Employees: 378
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 193,621,150
• 10 Day Avg. Volume: 65,506
• 30 Day Avg. Volume: 74,788
• PEG Ratio: 2.25
• Price to Book (P/B): 100.13
• Price to Sales (P/S): 65.25
• P/FCF Ratio: -132.57
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 21.08
• Enterprise Value/Gross Profit: 43.69
• Enterprise Value/Ebitda: -53.95
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $3.50 ▼(-45.48% Downside)

The score is held down primarily by weak financial performance (ongoing losses and negative operating cash flow) and bearish technicals (below key moving averages with negative MACD). Offsetting these are notably positive corporate events and rapid revenue/installation growth, but valuation remains constrained by unprofitability and no dividend support.

Positive Factors

Rapid revenue and installation growth

Sustained double-digit, multi-quarter top-line growth and a rapidly expanding installed base indicate strong product-market fit and accelerating adoption. A larger installed base supports recurring maintenance, services and upgrade revenue, improving long-term unit economics and market share.

Healthy gross margin and diversified revenue streams

A ~48% gross margin combined with diversified revenue (subscriptions, hardware, consulting, maintenance) supports durable gross profitability and recurring cash inflows. This mix helps absorb upfront hardware costs and underpins sustainable margin recovery as software and services scale.

Low leverage and strengthening balance sheet

Very low debt reduces financial risk and preserves strategic optionality for funding regulatory launches or international expansion. Rising equity suggests capital buffers to absorb near-term losses while management invests in commercialization and product development.

Negative Factors

Persistent operating losses and negative margins

Ongoing negative EBIT and net margins mean the business remains unprofitable despite revenue growth. Continued losses depress ROE and limit reinvestment capacity, forcing reliance on financing or equity issuance until operational leverage and scale convert top-line gains into sustainable profits.

Negative operating cash flow despite FCF growth

Negative operating cash flow signals the core business still consumes cash, creating funding pressure even as free cash flow metrics improve. Reliance on non‑operating or timing items to show FCF growth can mask underlying cash generation shortcomings that matter for durable liquidity.

Regulatory approvals pending for key markets

Expansion into large, higher‑margin U.S. and EU markets depends on FDA 510(k) and CE clearance. Approval delays, additional testing requests, or restricted indications could materially slow international commercialization and revenue diversification over the next several quarters.

SS Innovations International Business Overview & Revenue Model

Company Description

SS Innovations International, Inc. develops surgical robotic systems. It also develops SSI Mantra, a surgical robotic system; SSI Mudra, a range of surgical instruments that supports in surgical procedures, including robotic cardiac surgery; SSI Maya, a robotic surgery platform; and OMNI 3D HD provides live 3D HD view of the surgical field in robotic surgery operating room. The company is based in Fort Lauderdale, Florida.

How the Company Makes Money

SS Innovations International primarily generates revenue through multiple streams, including software licensing, hardware sales, and consulting services. The company sells its proprietary software solutions to enterprises on a subscription basis, which provides a steady income stream. Additionally, SSII generates revenue from the sale of specialized hardware products that complement its software offerings. Consulting services, including implementation support and training for clients, add another layer of revenue. Strategic partnerships with key industry players enhance SSII's market reach and provide access to new customers, further contributing to its earnings. The company also benefits from recurring revenue through maintenance and support contracts for its software and hardware solutions.

SS Innovations International Financial Statement Overview

Summary

Strong top-line momentum (TTM revenue growth +39%) and a healthy gross margin (48.25%) are positives, but persistent operating losses (negative EBIT and net margins), negative ROE, and negative operating cash flow keep overall financial quality weak despite lower leverage (debt-to-equity 0.07) and improved free cash flow growth.

Income Statement

SS Innovations International has shown significant revenue growth of 39% in the TTM period, indicating strong top-line expansion. However, the company struggles with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin is relatively healthy at 48.25%, but the negative EBIT and net profit margins highlight ongoing operational challenges.

Balance Sheet

The company's balance sheet shows improvement in the debt-to-equity ratio, which is now at a low 0.07, indicating reduced leverage. However, the return on equity remains negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the increase in stockholders' equity suggests a strengthening financial position.

Cash Flow

Cash flow analysis reveals a positive free cash flow growth rate of 27.09% in the TTM period, suggesting improved cash generation. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is below 1, indicating cash flow challenges. The free cash flow to net income ratio above 1 suggests efficient cash conversion despite losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.57M	20.65M	5.88M	1.46M	0.00	0.00
Gross Profit	16.20M	8.45M	713.45K	489.59K	-18.79K	-37.43K
EBITDA	-13.12M	-17.74M	-20.26M	-5.31M	-1.47M	-1.09M
Net Income	-17.11M	-19.15M	-20.94M	-5.60M	-1.48M	-1.12M
Balance Sheet
Total Assets	69.58M	42.39M	25.48M	6.98M	428.61K	317.87K
Cash, Cash Equivalents and Short-Term Investments	11.71M	466.50K	7.03M	217.18K	405.77K	160.71K
Total Debt	12.68M	18.20M	8.22M	8.27M	145.00K	195.00K
Total Liabilities	29.93M	28.93M	11.18M	9.66M	287.28K	1.19M
Stockholders Equity	39.65M	13.46M	14.30M	-2.68M	141.33K	-869.05K
Cash Flow
Free Cash Flow	-22.35M	-10.16M	-15.81M	-1.44M	-363.03K	-94.54K
Operating Cash Flow	-20.29M	-9.50M	-15.36M	-5.99M	-363.03K	-90.54K
Investing Cash Flow	-2.07M	-661.48K	-453.33K	240.82K	38.15K	-44.00K
Financing Cash Flow	28.20M	9.43M	22.80M	5.90M	569.95K	266.77K

SS Innovations International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SSII, the sentiment is Negative. The current price of 6.42 is above the 20-day moving average (MA) of 5.13, above the 50-day MA of 5.57, and below the 200-day MA of 6.75, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 26.56 is Positive, neither overbought nor oversold. The STOCH value of 12.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SSII.

SS Innovations International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNMD	65 Neutral	$1.21B	25.97	6.60%	2.02%	4.69%	-51.57%
TNDM	61 Neutral	$1.36B	-6.38	-109.73%	―	17.87%	-57.03%
ESTA	61 Neutral	$2.07B	-25.77	-338.19%	―	24.76%	-10.41%
AORT	58 Neutral	$1.95B	-172.02	-2.45%	―	9.81%	-1067.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SSII	45 Neutral	$708.65M	-57.48	-43.42%	―	159.43%	67.42%
IART	45 Neutral	$869.28M	-1.67	-38.71%	―	4.99%	-7151.40%

SS Innovations International Corporate Events

SS Innovations Reports Surging Preliminary 2025 Robotics Revenue

On January 13, 2026, SS Innovations International announced preliminary unaudited results indicating a sharp acceleration in sales of its SSi Mantra surgical robotic system for the fourth quarter and full year ended December 31, 2025. The company expects fourth-quarter 2025 revenue of about $15.0 million, an 85% increase from the prior-year period, driven by a 68% rise in SSi Mantra installations to 37 units, while full-year 2025 revenue is projected at roughly $43.0 million, up 108% year on year, with installations more than doubling to 103 units and lifting the global installed base to 168 systems. Management attributed the performance to strong demand in India and international markets and highlighted ongoing efforts to extend its footprint into the U.S. and Europe, where regulatory reviews are under way, underscoring the company’s bid to solidify its position in the growing surgical robotics market even as the figures remain preliminary and subject to final audit.

The most recent analyst rating on (SSII) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Unveils New 5mm Instruments for Robotic Surgery

On January 6, 2026, SS Innovations announced it had completed development of five new 5-millimeter surgical instruments—spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps—for use with its SSi Mantra robotic platform, targeting procedures in pediatric, cardiac, and head and neck surgery and other operations involving smaller anatomical structures. By addressing large, underserved patient populations, particularly children in lower- and middle-income countries who currently lack access to timely, safe surgical care, these smaller instruments are intended to extend the reach of robotic surgery beyond predominantly adult use and enhance the SSi Mantra system’s competitiveness in high-precision specialties, potentially strengthening the company’s position in emerging markets and expanding its role in complex cardiac and head and neck procedures.

The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations CEO Interview Published by Nasdaq

On November 13, 2025, Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations International, participated in an interview with Nasdaq’s Live From MarketSite. The interview was later published on December 16, 2025, and is available on both Nasdaq’s and the company’s websites. The information from the interview is considered ‘furnished’ and not ‘filed’ under the Securities Exchange Act of 1934, meaning it is not subject to the liabilities of that section.

The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Submits FDA Application for Robotic System

On December 8, 2025, SS Innovations International announced the submission of a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, targeting multiple specialties such as general, urological, and cardiac surgeries. This strategic move aims to introduce the cost-efficient system to the U.S. market, enhancing its appeal to hospitals and surgeons, particularly in underserved communities. The company is also progressing towards obtaining a European Union CE marking certification by the first half of 2026. As of November 30, 2025, the SSi Mantra has been installed in 138 systems across eight countries, with over 7,300 surgical procedures performed, highlighting its growing global footprint.

The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Unveils November 2025 Strategic Growth Plans

SS Innovations International has released an updated company presentation for November 2025, highlighting their growth and strategic plans. The company has seen significant sales growth and is expanding its global presence, with the SSi Mantra system already marketed in eight countries. The presentation underscores the company’s commitment to improving surgical robotics technology and its potential impact on the healthcare industry.

The most recent analyst rating on (SSII) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.

SS Innovations Completes First Telesurgery with New Console

On November 6, 2025, SS Innovations International announced the successful completion of the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC). This compact and portable console allows telesurgeries to be performed from various locations, including physician offices, without the need for a full operating room. The milestone surgery was conducted by Dr. Sudhir Srivastava from New Delhi, India, on a patient in Jaipur, India, highlighting the TSC’s ability to extend surgical expertise remotely. This development is expected to enhance patient access to surgical care and provide hospital networks with greater flexibility.

The most recent analyst rating on (SSII) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.